Cover Image
市場調查報告書

Netherton症候群(合入性裂毛症,結節性脆髮症):開發平台分析

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 321930
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Netherton症候群(合入性裂毛症,結節性脆髮症):開發平台分析 Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015
出版日期: 2015年12月09日 內容資訊: 英文 33 Pages
簡介

Netherton症候群是原因不明的罕見先天性皮膚疾病,被分類為魚鱗癬的一種。Netherton症候群是會影響皮膚、毛髮、免疫系統的疾病,其新生兒常患有紅皮症,出生時外表覆蓋有薄膜狀厚角化物質(珂珞酊薄膜)。

本報告提供Netherton症候群(合入性裂毛症,根據由於結節性脆髮症) 的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

Netherton症候群(合入性裂毛症,結節性脆髮症)概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Med Discovery SA
  • Novartis AG
  • SATT Lutech SAS
  • Skinvisible Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BPR-277
  • Drug to Inhibit Serine Proteinase for Netherton Syndrome
  • MDPK-67b
  • Small Molecules to Inhibit Kallikrein for Netherton Syndrome
  • Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7509IDB

Summary

Global Markets Direct's, 'Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015', provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) Overview
  • Therapeutics Development
    • Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Overview
    • Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Development by Companies
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Investigation by Universities/Institutes
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Development by Companies
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Investigation by Universities/Institutes
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Companies Involved in Therapeutics Development
    • Med Discovery SA
    • Novartis AG
    • SATT Lutech SAS
    • Skinvisible Pharmaceuticals, Inc.
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BPR-277 - Drug Profile
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Serine Proteinase for Netherton Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDPK-67b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kallikrein for Netherton Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), H2 2015
  • Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Med Discovery SA, H2 2015
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Novartis AG, H2 2015
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by SATT Lutech SAS, H2 2015
  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Skinvisible Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015

List of Figures

  • Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), H2 2015
  • Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top